Article
Oncology
Chi-Jung Wu, Pei-Chang Lee, Ya-Wen Hung, Chieh-Ju Lee, Chen-Ta Chi, I-Cheng Lee, Ming-Chih Hou, Yi-Hsiang Huang
Summary: This study evaluated the efficacy and safety of lenvatinib plus pembrolizumab for unresectable hepatocellular carcinoma (uHCC) patients. The results showed a high disease control rate (DCR) and no adverse effect on liver function score in both systemic therapy-naive and -experienced uHCC patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Hideki Iwamoto, Shigeo Shimose, Yu Noda, Tomotake Shirono, Takashi Niizeki, Masahito Nakano, Shusuke Okamura, Naoki Kamachi, Hiroyuki Suzuki, Miwa Sakai, Akira Kajiwara, Satoshi Itano, Masatoshi Tanaka, Taizo Yamaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Summary: The study retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC patients, showing that it remains effective and safe in real-world clinical practice.
Article
Gastroenterology & Hepatology
Xu Yang, Bowen Chen, Yanyu Wang, Yunchao Wang, Junyu Long, Nan Zhang, Jingnan Xue, Ziyu Xun, Linzhi Zhang, Jiamin Cheng, Jin Lei, Huishan Sun, Yiran Li, Jianzhen Lin, Fucun Xie, Dongxu Wang, Jie Pan, Ke Hu, Mei Guan, Li Huo, Jie Shi, Lingxiang Yu, Lin Zhou, Jinxue Zhou, Zhenhui Lu, Xiaobo Yang, Yilei Mao, Xinting Sang, Yinying Lu, Haitao Zhao
Summary: This study investigated the real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitor treatment in a large cohort of Asian uHCC patients. Despite the failure of the global LEAP-002 study, this study demonstrated long-term survival and significant response rates in Chinese patients treated with lenvatinib plus PD-1 inhibitors.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Oncology
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti
Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet
Summary: The combination of lenvatinib and pembrolizumab demonstrated sustained treatment effect in patients with first-line unresectable hepatocellular carcinoma (uHCC).
Article
Pharmacology & Pharmacy
Hsin-Yu Kuo, Meng-Zhi Han, Chih-Hsiang Liao, Yih-Jyh Lin, Chung-Teng Wang, Shang-Hung Chen, Ting-Tsung Chang, Po-Jun Chen, Sheng-Hsiang Lin, Chiung-Yu Chen, Chiao-Hsiung Chuang, I-Chin Wu, Juei-Seng Wu, Tzu-Chun Hong, Ming-Tsung Hsieh, Yang-Cheng Lee, Hung-Tsung Wu, Hong-Ming Tsai
Summary: This study investigated the differences in efficacy and safety between nivolumab and pembrolizumab in unresectable HCC patients. The results showed that pembrolizumab had a significantly higher objective response rate and overall survival compared to nivolumab.
Article
Medicine, General & Internal
V Makker, N. Colombo, A. Casado Herraez, A. D. Santin, E. Colomba, D. S. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. M. Guerra, U. A. Sanli, M. M. McCormack, A. D. Smith, S. Keefe, S. Bird, L. Dutta, R. J. Orlowski, D. Lorusso
Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Hsueh-Chien Chiang, Yang-Cheng Lee, Ting-Tsung Chang, Yih-Jyh Lin, Hung-Tsung Wu, Chung-Teng Wang, Chiung-Yu Chen, Po-Jun Chen, Ming-Tsung Hsieh, Sheng-Hsiang Lin, Shang-Hung Chen, Chiao-Hsiung Chuang, I-Chin Wu, Tzu-Chun Hong, Juei-Seng Wu, Meng-Zhi Han, Wei-Ting Chen, Chien-Ming Chiang, Kuan-Kai Hung, Hsin-Yu Kuo
Summary: Immunotherapy using immune checkpoint inhibitors (ICIs) combined with molecular targeted agents has shown potential synergic effects and superior efficacy in unresectable hepatocellular carcinoma (uHCC). This study compared the treatment efficacy of sorafenib versus lenvatinib in combination with PD-1 inhibitors in patients with uHCC. The results showed that PD-1 inhibitors combined with lenvatinib resulted in more favorable survival outcomes without increased toxic effects compared with PD-1 inhibitors with sorafenib.
Article
Oncology
Xiaowei Li, Zhigang Fu, Xiaoxia Chen, Kunkun Cao, Jiaming Zhong, Li Liu, Ning Ding, Xiaoli Zhang, Jian Zhai, Zengqiang Qu
Summary: This study demonstrates that LePD1-TACE triple therapy shows promising efficacy and manageable safety in Chinese patients with uHCC. Tumor number, NLR, and early tumor response may serve as prognostic markers.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon
Summary: In the first-line treatment of unresectable HCC, ATE/BEV and LENV had comparable clinical efficacy and safety, with no significant differences observed.
Article
Oncology
Myung Ji Goh, Joo Hyun Oh, Yewan Park, Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Summary: Lenvatinib therapy demonstrated favorable efficacy and safety in real-world practice, with an objective response rate of 18.9% and a disease control rate of 75.7% based on mRECIST criteria. Common adverse events included diarrhea, hand-foot skin rash, abdominal pain, hypertension, and anorexia.
Article
Oncology
Yun Zhu, Penghui Sun, Kunyuan Wang, Shuzhe Xiao, Yanling Cheng, Xiangzhao Li, Biao Wang, Jiancong Li, Wenxuan Yu, Yang Cheng
Summary: The study demonstrated that both lenvatinib monotherapy and lenvatinib-based combination therapy were well tolerated and effective in patients with unresectable hepatocellular carcinoma. Combination therapy showed superior efficacy compared to monotherapy, especially in patients who failed first-line treatment. Triple therapy with lenvatinib may not provide additional benefits over dual therapy.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Kang Chen, Wei Wei, Lei Liu, Zhu-Jian Deng, Le Li, Xiu-Mei Liang, Ping-Ping Guo, Lu-Nan Qi, Zhi-Ming Zhang, Wen-Feng Gong, Shan Huang, Wei-Ping Yuan, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong
Summary: In patients with unresectable hepatocellular carcinoma, combination therapy of lenvatinib and ICIs showed significantly improved efficacy and manageable safety compared to lenvatinib monotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Song Chen, Zhiqiang Wu, Feng Shi, Qicong Mai, Liguang Wang, Fan Wang, Wenquan Zhuang, Xiaoming Chen, Huanwei Chen, Bo Xu, Jiaming Lai, Wenbo Guo
Summary: This retrospective study compared the clinical outcomes of pembrolizumab-lenvatinib-TACE and lenvatinib-TACE sequential therapy in Chinese uHCC patients with initial PD-L1 expression, indicating that the former had a higher conversion rate, longer OS and PFS.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Kaoru Tsuchiya, Masayuki Kurosaki, Azusa Sakamoto, Hiroyuki Marusawa, Yuji Kojima, Chitomi Hasebe, Hirotaka Arai, Kouji Joko, Masahiko Kondo, Keiji Tsuji, Tetsuro Sohda, Hiroyuki Kimura, Chikara Ogawa, Yasushi Uchida, Shuichi Wada, Haruhiko Kobashi, Koichiro Furuta, Masaya Shigeno, Atsunori Kusakabe, Takehiro Akahane, Ryoichi Narita, Hideo Yoshida, Akeri Mitsuda, Yasushi Ide, Tomomichi Matsushita, Namiki Izumi
Summary: The first-line systemic therapy for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab therapy, and lenvatinib has shown high response rates in real-world practice for unresectable HCC patients in Japan. Pretreatment factors like ALBI score, AFP levels, and major vascular invasion play crucial roles in treatment strategy decisions for these patients.
